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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 222 (FGE.222): 
Consideration of genotoxicity data on representatives for alpha,beta-
unsaturated furyl derivatives with the α,β-unsaturation in the side chain 
from subgroup 4.6 of FGE.19 by EFSA1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate the genotoxic potential of six flavouring substances 
from subgroup 4.6 of FGE.19 in the Flavouring Group Evaluation 222. The Flavour Industry have 
provided additional genotoxicity studies for two representative substances, 3-(2-furyl)acrylaldehyde 
[FL-no: 13.034] and 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], in FGE.222. Based on these new data 
the Panel could not rule out a clastogenic and aneugenic potential for the two substances and a in vivo 
Comet assay was requested for both substances, the one including a micronucleus assay. 
© European Food Safety Authority, 2012 
KEY WORDS  
FGE.222, α,β-unsaturated aldehydes and ketones.  
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Scientific Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission 
on the implications for human health of chemically defined flavouring substances used in or on 
foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The present Flavouring Group Evaluation 222 (FGE.222), corresponding to subgroup 4.6 of FGE.19, 
concerns five α,β-unsaturated aldehydes and one ketone which are furyl derivatives with the α,β-
unsaturation in the side chain. The six substances under consideration in the present evaluation 
contain an α,β-unsaturated aldehyde or ketone structure which are structural alerts for genotoxicity 
and the data on genotoxicity previously available did not rule out the concern for genotoxicity. 
The Panel has identified two substances, 3-(2-Furyl)acrylaldehyde (furylacrolein) [FL-no: 13.034] and 
4-(2-Furyl)but-3-en-2-one (furfurylidene acetone) [FL-no: 13.044], in FGE.19 subgroup 4.6 which 
will represent the other four substances in this subgroup. For these two substances genotoxicity data 
according to the test strategy worked out by the Panel have been requested. 
The Industry has submitted data concerning genotoxicity studies for the two representative 
substances, 3-(2-furyl)acrylaldehyde [FL-no: 13.034] and 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], 
for this subgroup. 
Based on the data submitted the Panel considered that in order to clarify the clastogenic and aneugenic 
potential of 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], an in vivo Comet assay should be performed 
and for 3-(2-furyl)acrylaldehyde [FL-no: 13.034], an in vivo combined Comet and micronucleus assay 
should be performed. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union list of flavouring substances for use in or 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and/or oxidation (EFSA, 2008b). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The  α,β-unsaturated carbonyls were subdivided into 28 subgroups on the basis of structural similarity 
(EFSA, 2008b). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these  α,β-unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225). 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
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Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To easy the data retrieval of the large number of structurally related  α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA has worked out a list of 
representative substances for each subgroup (EFSA, 2008bc). Likewise an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008bb).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.   
The Flavouring Industry has now submitted additional data on representative substances of subgroup 
4.6 and the present FGE concerns the evaluation of these data requested on genotoxicity. 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances prior to their authorisation and inclusion in a Union list according to Commission 
Regulation (EC) No 1565/2000 (EC, 2000a). 
In addition, in letter of 23 January 2012, the European Commission requests the European Food Safety 
Authority to carry out a safety assessment on the following six substances, 3-(2-furyl)acrylaldehyde 
[FL-no: 13.034], furfurylidene-2-butanal [FL-no: 13.043], 4-(2-furyl]but-3-en-2-one [FL-no: 13.044], 
3-(2-furyl]-2-methylprop-2-enal [FL-no: 13.046], 3(2-furyl)-2-phenylprop-2-enal [FL-no: 13.137] and 
3(5-methyl-2-furyl)prop-2-enal [FL-no: 13.150], in accordance with Commission Regulation (EC) N° 
1565/2000. 
ASSESSMENT 
1. Presentation of the substances in the Flavouring Group 
1.1. Description 
The present Flavouring Group Evaluation 222 (FGE.222), corresponding to subgroup 4.6 of FGE.19 
(EFSA, 2008b), concerns five α,β-unsaturated aldehydes and one ketone which are furyl derivatives 
with the α,β-unsaturation in the side chain. The six substances under consideration in the present 
evaluation are listed in Table 6.  
All six substances have previously been evaluated by the JECFA at their 65th and 69th meetings 
(JECFA, 2006b; JECFA, 2009c). At the latest meeting it was concluded “that the Procedure could not 
be applied to this group because of the unresolved toxicological concerns”. A summary of their current 
evaluation status by the JECFA and the outcome of this consideration is presented in Table 7. 
The α,β-unsaturated aldehyde and ketone structures are considered to be structural alerts for 
genotoxicity (EFSA, 2008b) and the data on genotoxicity previously available did not rule out this 
concern for genotoxicity. 
1.2. Representative substances for subgroup 4.6 
The Panel has identified two substances in subgroup 4.6 which will represent the other four substances 
in this subgroup (EFSA, 2008bc). For these two substances genotoxicity data according to the test 
strategy (EFSA, 2008bb) have been requested. The representative substances are listed in Table 1. 
Table 1:  Representative substances for subgroup 4.6 of FGE.19  
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FL-no  
JECFA-no  
Subgroup  EU Register name  Structural formula  FEMA no  
CoE no  
CAS no  
13.034 
1497  
4.6  3-(2-Furyl)acrylaldehyde O
O
 
2494 
2252 
623-30-3 
13.044 
1511 
4.6  4-(2-Furyl)but-3-en-2-one 
O
O 2495 
11838 
623-15-4 
 
2. Additionally submitted genotoxicity data on representative substances of subgroup 4.6 
The Industry has submitted data concerning genotoxicity studies for the two representative substances 
for this subgroup (EFFA, 2011q). 
• 3-(2-Furyl)acrylaldehyde (furylacrolein) [FL-no: 13.034] 
• 4-(2-Furyl)but-3-en-2-one (furfurylidene acetone) [FL-no: 13.044]. 
2.1. In vitro data 
In vitro genotoxicity assays have been performed on both representative substances. 
2.1.1. 3-(2-Furyl)acrylaldehyde (furylacrolein) 
2.1.1.1. Bacterial Reverse Mutation Assay 
3-(2-Furyl)acrylaldehyde [FL-no: 13.034] was reported as non mutagenic in a valid GLP study with 
Ames test using five S.typhimurium strains (TA98, TA100, TA1535, TA1537 and TA102) in the 
presence and absence of metabolic activation (S9) up to acceptable top concentrations (5000 
micrograms/plate) (Lillford, 2010) (Table 8). 
2.1.1.2. In vitro micronucleus assays 
3-(2-Furyl)acrylaldehyde [FL-no: 13.034] was tested in a GLP/OECD in vitro micronucleus assay in 
human lymphocyte cultures in the presence and absence of metabolic activation (S9)(Whitwell, 
2010d) (Table 8). 
Cells were stimulated with phytohaemagglutinin (PHA) and then treated for 3 hours (followed by 21 
hours recovery) with 0, 50, 75, 120 and 150 μg/ml of 3-(2-furyl)acrylaldehyde in the absence of S9 
and 0, 50, 65 and 90 μg/ml in the presence of S9, respectively. The levels of toxicity (reduction in 
replication index) at the top concentrations in the absence and presence of S9 were 61 and 59 %, 
respectively. In a parallel assay, cells were treated with 0, 25, 30 and 40 μg//ml of 3-(2-
furyl)acrylaldehyde for 24 hours in the absence of S9 with no recovery period. In this assay, the top 
concentration induced 55 % cytotoxicity (Table 2). There were two replicate cultures per treatment 
and 1000 binucleate cells per replicate (i.e., 2000 cells per dose) were scored for micronuclei. 
As shown in Table 2, at the two highest concentrations (65 and 90 μg/ml) in the 3 + 21 hours 
treatment in the presence of S9, the frequencies of micronucleated binucleate cells (MNBN) (0.65 and 
0.85 %) were significantly (p≤0.05 and p≤0.01) higher than the concurrent control (0.30 %), with 23 
% and 59 % cytotoxicity values, respectively. The increased frequencies fell within the historical 
control range (0.0 - 1.2 %). Both treatments in the absence of S9 (pulse 3 + 21 hours and continuous 
24 + 0 hours) showed no significant increases in the MNBN frequencies compared with the concurrent 
vehicle control.  
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To further investigate the conditions under which the statistically significant increases were observed, 
3-(2-furyl)acrylaldehyde was re-tested with the 3 + 21 hours treatment in the presence of S9 
(Whitwell, 2011b) (Table 8).  
As shown in Table 3, concentrations of 55, 70, 95 and 110 μg/ml resulted in mean MNBN cell 
frequencies of 0.35 % (16 % cytototoxicity), 1.20 % (25 % cytotoxicity), 0.70 % (49 % cytotoxicity) 
and 0.55 % ( 51 % cytotoxicity), compared to 0.30 % in the concurrent vehicle control. At the two 
intermediate concentrations (70 and 95 μg/ml) statistically significant (p≤0.001 and p≤0.05) increases 
in the frequency of MNBN cells were observed  compared with the concurrent vehicle control. With 
the exception of one single culture at an intermediate concentration (70 μg/ml), the MNBN cell 
frequencies of all treated cultures fell within historical control range (0.10 - 1.10 %). In view of the 
reproducibility of response between two separately conducted studies, the small but statistically 
significant increases in MNBN, observed also at levels not excessively toxic in the presence of S9, 
were considered indicative of a weak clastogenic or aneugenic potential for 3-(2-furyl)acrylaldehyde 
[FL-no: 13.034] in the presence of metabolic activation. 
In conclusion, though the micronucleus frequencies mostly felt within historical control ranges, the 
statistically significant increases were reproducible and therefore considered indicative of a weak 
clastogenic or aneugenic potential. 
The details and conclusions for the Micronucleous assays on 3-(2-furyl)acrylaldehyde described above 
are summarised in Tables 2, 3 and 8. 
2.1.2. 4-(2-Furyl)but-3-en-2-one (furfurylidene acetone) 
2.1.2.1. Bacterial Reverse Mutation Assay 
Previously available in vitro genotoxicity data 
4-(2-Furyl)but-3-en-2-one [FL-no: 13.044] was reported as non mutagenic in the Ames test using four 
S. typhimurium strains (TA98, TA100, TA1535 and TA1537) in the presence and absence of the S9 
fractions, at concentrations of 0, 33, 100, 333, 1000 and 3333 μg/plate (Mortelmans et al., 1986). This 
publication reports the results of the Ames test on 270 chemicals tested by three laboratories under 
contract to the US. National Toxicology Program (NTP) (Table 8). 
Additional genotoxicity data 
4-(2-Furyl)but-3-en-2-one [FL-no: 13.044] was tested in a top-up GLP study in S. typhimurium TA102 
strain in the presence and absence of S9 up to 5000 micrograms/plate (Kilford, 2010). Overall the 
study data, when combined with the published results in four other strains (Mortelmans et al., 1986), 
achieve compliance with current OECD recommendations (Table 8). 
As in the Mortelmans et al. study (1986), no increases in revertant numbers were observed. It was 
therefore concluded that 4-(2-furyl)but-3-en-2-one, while already shown not to be mutagenic in strains 
TA98, TA100, TA1535 and TA1537, is neither mutagenic for TA102 at concentrations up to the 
maximum  required which caused bactericidal effects. 
2.1.2.2. In vitro micronucleus assays 
4-(2-Furyl)but-3-en-2-one [FL-no: 13.044] was tested in a GLP/OECD in vitro micronucleus assay in 
human lymphocyte cultures in the absence and presence of S9-mix (Lloyd, 2009b). The study was 
performed in compliance with OECD Test Guideline 487 (Table 8). 
After stimulation for 48 hours with phytohaemagglutinin (PHA) cells were treated for 3 hours  
(followed by 21 hours recovery) with 0, 100, 250 and 300 μg/ml of 4-(2-furyl)but-3-en-2-one  in the 
absence of S9 and 0, 65, 80 and 100 μg/ml in the presence of S9, respectively. The levels of toxicity at 
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the top concentrations in the absence and presence of S9 were 57 and 52 %, respectively. In a parallel 
experiment, cells were treated with 0, 40, 55 and 65 μg/ml of 4-(2-furyl)but-3-en-2-one for 24 hours in 
the absence of S9, with no recovery period. In this experiment, the top concentration induced 56 % 
cytotoxicity (Table 4). There were two replicate cultures per treatment and 1000 binucleate cells per 
replicate (i.e., 2000 cells per concentration) were scored for micronuclei.  
As reported in Table 4 with the results summary, at the highest concentration (300 μg/ml) in the 3 + 21 
hours treatment in the absence of S9, the MNBN cell frequency (0.75 %, with 57 % cytotoxicity) was 
significantly (p≤0.01) higher than the concurrent vehicle control (0.15 %), however, it was within the 
historical control range (0.0 - 1.0 %). The MNBN cell frequencies in all other treatment conditions 
were not statistically significantly increased and fell within the normal ranges. 
To further investigate the conditions under which the small statistical increase was observed, 4-(2-
furyl)but-3-en-2-one was re-tested with the 3+21 hours treatment in the absence of S9-mix (Lloyd, 
2011d).  
As reported in Table 5 with the results summary, the concentrations used (0, 100, 250, 300 and 325 
μg/ml) resulted in mean MNBN cell frequencies of 0.40 %,  0.45 % (23 % cytotoxicity), 0.50 % (36 % 
cytotoxicity), 0.65 % (46 % cytotoxicity) and 1.55 % (52 % cytotoxicity). At the top concentration 
(325 μg/ml) with 52 % cytotoxicity, the frequency of MNBN cells (1.55 %) was significantly 
(p≤0.001) higher compared to that observed in concurrent vehicle control (0.40 %). The MNBN cell 
frequencies in both cultures at 325 μg/ml exceeded the 95th percentile of the historical control range 
(0.2 - 0.8 %). At 300 μg/ml, with 46 % cytotoxicity, the frequency of MNBN cells (0.65 %) was 
similar to that observed in concurrent vehicle control (0.40 %) and the MNBN cell frequencies in both 
cultures fell within the normal range.  
It was concluded that 4-(2-furyl)but-3-en-2-one [FL-no: 13.044] induced micronuclei when tested at 
the top concentrations of 300 and 325 μg/ml for 3 + 21 hours treatment in the absence of metabolic 
activation (S9) in two independent studies. 
The details and conclusions for the Micronucleous assays on 4-(2-furyl)but-3-en-2-one described 
above are summarised in Tables 4, 5 and 8. 
2.2. In vivo data 
No in vivo data are available for the two representative substances for subgroup 4.6. 
3. Conclusion 
3-(2-Furyl)acrylaldehyde [FL-no: 13.034] was negative in the Ames test. In the in vitro micronucleus 
assay, statistically significant and reproducible increases in MNBN cells frequencies were observed in 
two separate studies in the presence of metabolic activation (S9) with the effect observed at modest 
levels of cytotoxicity. In the first study the increases were seen at the two top concentrations and in the 
second study, the increases were observed at two intermediate concentrations. Even though the 
micronucleus frequencies in the treated cells felt in most of the occasions within the historical control 
ranges, the reproducibility of statistically significant increases in MNBN cells in the presence of S9 in 
two separate studies, observed at modest levels of cytotoxicity, was considered indicative of a 
clastogenic or aneugenic potential for 3-(2-furyl)acrylaldehyde. 
The Panel considered that in order to clarify the clastogenic and aneugenic potential of 3-(2-
furyl)acrylaldehyde [FL-no: 13.034] an in vivo combined Comet and micronucleus assay by oral route 
in rodents should be performed. As the in vitro effect was observed in the presence of metabolic 
activation the Comet assay should include an investigation of the liver. The combined study has to be 
preferred to an in vivo micronucleus assay, in view of the possibility that a genotoxic metabolite of 3-
(2-furyl)acrylaldehyde does not reach the target (bone marrow cells) in sufficient amount. 
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4-(2-Furyl)but-3-en-2-one [FL-no: 13.044] was negative in the Ames test. In the in vitro micronucleus 
assay, statistically significant and reproducible increases in MNBN cells were observed in two 
separate studies in the absence of metabolic activation (S9) at the top concentration. Though the 
results observed in the first study felt within the historical control range, the Panel considered that in 
order to clarify the clastogenic and aneugenic potential of 4-(2-furyl)but-3-en-2-one, an in vivo Comet 
assay in rodents should be performed. As the in vitro effect was observed in the absence of metabolic 
activation, the Panel considered an in vivo Comet assay more appropriate than an in vivo micronucleus 
assay. The Comet assay should include evaluation of first site of contact following oral administration 
(e.g. stomach or duodenum), since in vitro the effects were observed in the absence of S9 and the 
micronucleus assay in bone marrow is not appropriate to detect effects occurring in first site of contact 
tissues. 
In conclusion the available data do not rule out the concern for genotoxicity.  
 
 
 
Flavouring Group Evaluation 222
 
EFSA Journal 2012;10(5):2748 10
STUDY DETAILS REPORTED 
Table 2:  In Vitro Micronucleus Assay (48 hours PHA) – Results Summary (Whitwell, 2010d) 
Test substance Treatment Concentration (μg/ml) Cytotoxicity (%) Mean MNBN cell 
frequency (%) 
Historical Control 
Range (%) # 
Statistical 
significance 
3-(2-Furyl)acrylaldehyde 3+21 hours 
-S-9 
Vehiclea 
50.00 
75.00 
120.0 
150.0 
*MMC, 0.80 
- 
10 
31 
49 
61 
ND 
0.70 
0.45 
0.55 
0.40 
0.50 
8.60 
0.1-1.2 - 
NS 
NS 
NS 
NS p ≤ 0.001 
 3+21 hours 
+S-9 (Trial 2) 
Vehiclea
50.00 
65.00 
90.00 
*CPA, 6.25   
*CPA, 12.5 
- 
4 
23 
59 
ND 
ND 
0.30 
0.20 
0.65 
0.85 
1.50 
2.35 
0.0-1.2 - 
NS 
p ≤ 0.05 
p ≤ 0.01 
p ≤ 0.001 
p ≤ 0.001 
 24+0 hours 
-S-9 
Vehiclea 25.00  30.00  40.00  
*VIN, 0.02 
- 
16 
23 
55 
ND 
0.65 
0.35 
0.45 
0.95 
9.63 
0.1-1.2 - 
NS 
NS 
NS 
p ≤ 0.001 
 
 
Table 3:  In Vitro Micronucleus Assay (48 hours PHA) – Results Summary (Whitwell, 2011b) 
Test substance Treatment Concentration (μg/ml) Cytotoxicity (%) Mean MNBN cell 
frequency (%) 
Historical Control 
Range (%)# 
Statistical 
significance 
3-(2-furyl)acrylaldehyde 3+21 hours  
+S-9 
Vehiclea
55.00 
70.00 
95.00 
110.0 
*CPA, 12.5 
- 
16 
25 
49 
51 
ND 
0.30 
0.35 
1.20 
0.70 
0.55 
2.10 
0.10-1.10 - 
NS 
p ≤ 0.001 
p ≤ 0.05 
NS 
p ≤ 0.001 
a Vehicle control was DMSO. 
* Positive control. 
#95th  percentile of the observed range. 
NS = Not significant. 
ND = Not determined. 
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Table 4:  In Vitro Micronucleus Assay – Results summary (Lloyd, 2009b) 
Test substance Treatment Concentration (μg/ml) Cytotoxicity (%) Mean MNBN cell 
frequency (%) 
Historical Control 
Range (%) # 
Statistical 
significance 
4-(2-Furyl)but-3-en-2-one 3+21 hours  
-S-9 
Vehiclea 
100.0 
250.0 
300.0 
*MMC, 0.8 
- 
13 
30 
57 
ND 
0.15 
0.25 
0.25 
0.75 
16.20 
0.0-1.0 - 
NS 
NS 
p ≤ 0.01 
p ≤ 0.001 
 3+21 hours  
+S-9 
Vehiclea 
65.00 
80.00 
100.00 
*CPA, 6.25 
- 
14 
29 
52 
ND 
0.20 
0.30 
0.15 
0.30 
2.10 
0.1-0.8 - 
NS 
NS 
NS 
p ≤ 0.001 
 24+0 hours  
-S-9 
Vehiclea 
40.00 
55.00 
65.00 
*VIN, 0.02 
- 
8 
33 
56 
ND 
0.10 
0.10 
0.20 
0.05 
9.05 
0.0-1.0 - 
NS 
NS 
NS 
p ≤ 0.001 
 
Table 5:  In Vitro Micronucleus Assay – Results Summary (Lloyd, 2011d) 
Test substance Treatment Concentration 
(μg/ml) 
Cytotoxicity 
(%) 
Mean MNBN cell 
frequency (%) 
Historical Control 
Range (%) # 
Statistical 
significance 
4-(2-Furyl)but-3-en-2-one 3+21 hours  
-S-9 
Vehiclea 
100.0 
250.0 
300.0 
325.0 
*MMC, 0.6 
- 
23 
36 
46 
52 
ND 
0.40 
0.45 
0.50 
0.65 
1.55 
12.90 
0.2-0.8 - 
NS 
NS 
NS 
p ≤ 0.001 
p ≤ 0.001 
a Vehicle control was DMSO.  
* Positive control. 
# 95th  percentile of the calculated range. 
NS = not significant.  
ND = not determined. 
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SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 222  
Table 6:  Specification Summary of the Substances in the present group (JECFA, 2009b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
13.034 
1497 
3-(2-Furyl)acrylaldehyde O O
 
2494 
2252 
623-30-3 
Solid 
C7H6O2 
122.12 
Insoluble 
Soluble 
n.a. 
49-52 
NMR 
97 % 
 
 
13.043 
1501 
Furfurylidene-2-butanal O
O
 
2492 
11885 
770-27-4 
Liquid 
C9H10O2 
150.18 
Insoluble 
Soluble 
240 
 
NMR 
98 % 
1.570-1.576 
1.057-1.063 
13.044 
1511 
4-(2-Furyl)but-3-en-2-one 
O
O
 
2495 
11838 
623-15-4 
Solid 
C8H8O2 
136.15 
Insoluble 
Soluble 
n.a. 
37-40 
NMR 
98 % 
n.a. 
n.a. 
13.046 
1498 
3-(2-Furyl)-2-methylprop-2-enal 
O
O
 
2704 
11878 
874-66-8 
Liquid 
C8H8O2 
136.15 
Insoluble 
Soluble 
225 
 
NMR 
96 % 
1.567-1.573 
1.097-1.103 
13.137 
1502 
3-(2-Furyl)-2-phenylprop-2-enal O O
 
3586 
11928 
65545-81-5 
Solid 
C13H10O2 
198.22 
Insoluble 
Soluble 
n.a. 
56-57 
NMR 
99 % 
n.a. 
n.a. 
13.150 
1499 
3-(5-Methyl-2-furyl)prop-2-enal O O
 
4175 
 
5555-90-8 
Liquid 
C8H8O2 
136.15 
Slightly soluble 
Soluble 
101 (7 hPa) 
 
NMR 
95 % 
1.006-1.012 
0.998-1.004 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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CURRENT SAFETY EVALUATION STATUS APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH)  
Table 7:  Summary of Safety Evaluation of the JECFA substances in the present group (JECFA, 2009c) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
JECFA Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
 
13.034 
1497 
3-(2-Furyl)acrylaldehyde O O
 
0.037 
0.4 
Class II 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required.  
13.044 
1511 
4-(2-Furyl)but-3-en-2-one 
O
O
 
1.6 
1 
Class II 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required. 
13.150 
1499 
3-(5-Methyl-2-furyl)prop-2-
enal 
O
O
 
0.0012 
0.002 
Class II 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required. 
13.043 
1501 
Furfurylidene-2-butanal O
O
 
ND 
0.007 
Class III 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required. 
13.046 
1498 
3-(2-Furyl)-2-methylprop-2-
enal O
O 0.24 
6 
Class III 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required. 
13.137 
1502 
3-(2-Furyl)-2-phenylprop-2-
enal 
O
O ND 
0.007 
Class III 
No evaluation 
Further data required Evaluated in FGE.222, 
additional genotoxicity data 
required. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined. 
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GENOTOXICITY (IN VITRO)  
Table 8:  Summary of Additionally submitted genotoxicity data on the representative substance of subgroup 1.2.3 
FL-no Chemical Name Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
[13.034] 3-(2-Furyl)acrylaldehyde Reverse 
Mutation 
S. typhimurium 
TA100 
1.6, 8, 40, 200, 1000 and 
5000 μg/plate [1,2]
Negative (Lillford, 2010) Toxicity observed in all 
strains at 1000 and/or 5000 
μg/plate or greater in the 
presence and absence of S-9. 
S. typhimurium 
TA98, TA1535, 
TA1537 and TA102 
0.32, 1.6, 8, 40, 200, 1000 
and 5000 μg/plate [1,2] 
Negative 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
and TA102 
8.192, 20.48, 51.2, 128, 
320, 800, 2000 and 5000 
μg/plate [2,3]
Negative Toxicity observed in all 
strains at 5000 μg/plate in the 
absence of S-9. 
8.192, 20.48, 51.2, 128, 
320, 800, 2000 and 5000 
μg/plate [4,5]
Negative Toxicity observed at 800 and 
2000 μg/plate in presence of 
S-9 with preincubation. 
Micronucleus 
induction 
Human peripheral 
blood lymphocytes 
50, 75, 120, and 150 μg/ml 
[3,6]; 
50, 65 and 90 μg/ml [5,6] 
Positive at top 2 
concentrations [5] 
(Whitwell, 
2010d) 
Complies with OECD 
guideline 487. Acceptable 
levels of cytotoxicity were 
achieved at the top 
concentrations used in all 
parts of the study.
25, 30 and 40 μg/ml [3,7] Negative 
55, 70, 95 and 110 μg/ml 
[5,6] 
Positive at 
intermediate 
concentrations; 
negative at top 
concentration tested 
[5]
(Whitwell, 
2011b) 
Complies with OECD 
guideline 487. Acceptable 
levels of cytotoxicity were 
achieved at the top 
concentrations used in all 
parts of the study.
[13.044] 4-(2-Furyl)but-3-en-2-one Reverse 
Mutation 
S. typhimurium 
TA102 
1.6, 8, 40, 200, 1000 and 
5000 μg/plate [1,2]
Negative (Kilford, 2010) Toxicity observed in all 
strains at 5000 μg/plate. 
78.13, 156.13, 312.5, 625, 
1250, 2500 and 5000 
μg/plate [2,3]
Negative Toxicity observed in all 
strains at 2500 μg/plate or 
greater.
78.13, 156.13, 312.5, 625, 
1250, 2500 and 5000 
μg/plate [4,5]
Negative  
S. typhimurium 
TA98, TA100, 
33, 100, 333, 1000, 2166 
and 3333 μg/plate [1,4] 
Negative (Mortelmans et 
al., 1986) 
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Table 8:  Summary of Additionally submitted genotoxicity data on the representative substance of subgroup 1.2.3 
FL-no Chemical Name Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
TA1535 and 
TA1537 
Micronucleus 
induction 
Human peripheral 
blood lymphocytes 
100, 250, and 300 μg/ml 
[3,6]; 
65, 80 and 100 μg/ml [5,6] 
Positive only at > 50 
% cytotoxicity [3] 
(Lloyd, 2009b) Complies with OECD 
guideline 487. Acceptable 
levels of cytotoxicity were 
achieved at the top 
concentrations used in all 
parts of the study. 
40, 55 and 65 μg/ml [3,7] Negative 
100, 250, 300, and 325 
μg/ml [3,6] 
Positive only at top 
concentration, which 
induced > 50 % 
toxicity and was too 
cytotoxic to score in a 
previous study 
(Lloyd, 2011d) Complies with OECD 
guideline 487. Acceptable 
levels of cytotoxicity were 
achieved at the top 
concentrations used in all 
parts of the study. 
[1] With and without S-9 metabolic activation. 
[2] Plate incorporation method. 
[3] Without S-9 metabolic activation. 
[4] Pre-incubation method. 
[5] With S-9 metabolic activation. 
[6] 3-hours incubation with 21-hours recovery period. 
[7] 24-hours incubation with no recovery period. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
DMSO  Dimethyl sulfoxide 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNBN  MicroNucleated BiNucleate cells 
MS  Masse spectra 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NMR  Nuclear Magnetic Resonance 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PHA  Phytohaemagglutinin  
(Q)SAR (Quantitative ) Structure Activity Relationship 
SCF  Scientific Committee on Food 
WHO  World Health Organisation 
